Further, patients who received AC vs those who did not were compared with respect to their overall survival.
Retrospective cohort study including 2,569 patients 80 years and older who underwent pancreaticoduodenectomy for pancreatic cancer between 2004 and 2016; 47.4% of these patients received adjuvant chemotherapy.
The adjuvant chemotherapy group had significantly longer median overall survival across the overall cohort, the propensity-matched cohort, and all subgroups.
Based on findings, they suggest further exploration of the adjuvant treatment paradigms for patients 80 years and older with PDAC, as there seems to be a group of patients who could benefit from curative intent with surgery and chemotherapy. Read more . . .